Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer-Reference-Cited by-同舟云学术

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer

Published:2021-06 Issue:3 Volume:161 Page:676-680
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Rocconi Rodney P.,Monk Bradley J.,Walter Adam,Herzog Thomas J.,Galanis Evanthia,Manning Luisa,Bognar Ernest,Wallraven Gladice,Stanbery Laura,Aaron Phylicia,Senzer Neil,Coleman Robert L.,Nemunaitis John

Funder

MedImmune

Bristol-Myers Squibb

Genentech

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference17 articles.

1. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis;Xu;Oncotarget,2017

2. Ovarian cancer stem cells and targeted therapy;Keyvani;J. Ovarian Res.,2019

3. BRCA1/2 mutation status impact on autophagy and immune response: unheralded target;Morand;JNCI Cancer Spectrum,2020

4. Niraparib in patients with newly diagnosed advanced ovarian cancer;Gonzalez-Martin;N. Engl. J. Med.,2019

5. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer;Tewari;J. Clin. Oncol.,2019

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

2. Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides;Journal of Clinical Oncology;2024-07-31

3. 3D engineered scaffold for large-scale Vigil immunotherapy production;Scientific Reports;2024-07-05

4. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04

5. TGF-β signaling in health, disease and therapeutics;Signal Transduction and Targeted Therapy;2024-03-22